Title
Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA
Date Issued
01 August 2017
Access level
open access
Resource Type
journal article
Author(s)
Metcalf B.J.
Chochua S.
Gertz R.E.
Hawkins P.A.
Li Z.
Walker H.
Tran T.
Rivers J.
Mathis S.
Jackson D.
McGee L.
Beall B.
Glennen A.
Lynfield R.
Reingold A.
Brooks S.
Randel H.
Miller L.
White B.
Aragon D.
Barnes M.
Sadlowski J.
Petit S.
Cartter M.
Marquez C.
Wilson M.
Farley M.
Thomas S.
Tunali A.
Baughman W.
Harrison L.
Benton J.
Carter T.
Hollick R.
Holmes K.
Riner A.
Holtzman C.
Danila R.
MacInnes K.
Scherzinger K.
Angeles K.
Bareta J.
Butler L.
Khanlian S.
Mansmann R.
Nichols M.
Bennett N.
Zansky S.
Currenti S.
McGuire S.
Thomas A.
Schmidt M.
Thompson J.
Poissant T.
Schaffner W.
Barnes B.
Leib K.
Dyer K.
McKnight L.
Almendares O.
Hudson J.
McGlone L.
Whitney C.
Schrag S.
Langley G.
Centros para el Control y la Prevención de Enfermedades
Publisher(s)
Elsevier
Abstract
Objectives Our objective was to evaluate and exploit a whole genome sequence (WGS) bioinformatics pipeline for predicting antimicrobial resistance and capsular serotypes from invasive group B streptococci (iGBS). Methods For 1975 iGBS recovered during 2015 from CDC's Active Bacterial Core surveillance, we compared pipeline predictions with broth dilution testing. Fifty-six isolates from earlier surveillance were included for testing β-lactams. Conventional serotyping was compared to WGS-based assignments for 302 isolates. Results All 28 isolates with reduced susceptibility to β-lactam antibiotics harboured one of 19 rare PBP2x types. Resistances to erythromycin/clindamycin (808/1975 isolates, 41.0%), erythromycin (235/1975, 11.9%) and lincosamide/streptogramin A/pleuromutilins (56/1975, 2.8%) were predicted by the presence of erm-methylase, mef and lsa determinants, respectively (41 of 56 lsa gene-positive isolates also contained lnu, erm and/or mef genes). Presence of both erm and lsa determinants (25 isolates) predicted non-susceptibility to quinupristin/dalfopristin. Most isolates (1680/1975, 85.1%) were tet gene-positive, although 41/1565 (2.6%) tetM-positive isolates were tetracycline-susceptible. All 53 fluoroquinolone-resistant isolates contained ParC and/or GyrA substitutions. Resistances to rifampin (eight isolates), trimethoprim, chloramphenicol and vancomycin (two isolates each) were predicted by the pipeline. Resistance to macrolides/lincosamides without pipeline prediction was rare and correlated to divergent resistance genes or rRNA A2062G substitution. A selection of 267 isolates assigned WGS-based serotypes were also conventionally serotyped. Of these, 246 (92.1%) were in agreement, with the remaining 21 (7.8%) conventionally non-serotypeable. For 32 of 1975 isolates (1.6%), WGS-based serotypes could not be assigned. Conclusion The WGS-based assignment of iGBS resistance features and serotypes is an accurate substitute for phenotypic testing.
Start page
574.e7
End page
574.e14
Volume
23
Issue
8
Language
English
OCDE Knowledge area
Biología celular, Microbiología
Subjects
Scopus EID
2-s2.0-85017186770
PubMed ID
Source
Clinical Microbiology and Infection
ISSN of the container
1198743X
Sponsor(s)
We thank the following individuals for their contributions to the establishment and maintenance of the ABCs system: California Emerging Infections Program: A. Reingold, S. Brooks and H. Randel; Colorado Emerging Infections Program: L. Miller, B. White, D. Aragon, M. Barnes and J. Sadlowski; Connecticut Emerging Infections Program: S. Petit, M. Cartter, C. Marquez and M. Wilson; Georgia Emerging Infections Program: M. Farley, S. Thomas, A. Tunali and W. Baughman; Maryland Emerging Infections Program: L. Harrison, J. Benton, T. Carter, R. Hollick, K. Holmes and A. Riner; Minnesota Emerging Infections Program: C. Holtzman, R. Danila and K. MacInnes; New Mexico Emerging Infections Program: K. Scherzinger, K. Angeles, J. Bareta, L. Butler, S. Khanlian, R. Mansmann and M. Nichols; New York Emerging Infections Program: N. Bennett, S. Zansky, S. Currenti and S. McGuire; Oregon Emerging Infections Program: A. Thomas, M. Schmidt, J. Thompson and T. Poissant; Tennessee Emerging Infections Program: W. Schaffner, B. Barnes, K. Leib, K. Dyer, and L. McKnight; CDC: O. Almendares, J. Hudson, L. McGlone, Cynthia Whitney, S. Schrag and G. Langley. This publication made use of the Streptococcus agalactiae MLST website (http://pubmlst.org/ sagalactiae/) sited at the University of Oxford (Jolley & Maiden BMC Bioinformatics 2010;11:595). The development of this site has been funded by the Wellcome Trust. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.
Sources of information:
Directorio de Producción Científica
Scopus